Search Results for "calcium"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for calcium. Results 191 to 200 of 216 total matches.
Choice of Contraceptives
The Medical Letter on Drugs and Therapeutics • May 15, 2023 (Issue 1676)
)
Drospirenone/ethinyl estradiol
(3 mg/30 mcg [21 days], levomefolate calcium [7 days])
Safyral (Bayer)
Tydemy ...
Intrauterine devices (IUDs) and the etonogestrel
implant are the most effective reversible contraceptive
methods available. Hormonal oral contraceptives,
patches, rings, and injectables are also effective in
preventing pregnancy. When used alone, barrier and
behavioral methods generally have higher failure
rates than other methods (see Table 1). Selection of
a contraceptive method is usually based on patient-specific factors and personal preference
Med Lett Drugs Ther. 2023 May 15;65(1676):73-80 doi:10.58347/tml.2023.1676a | Show Introduction Hide Introduction
Pitolisant (Wakix) for Narcolepsy
The Medical Letter on Drugs and Therapeutics • Feb 08, 2021 (Issue 1617)
available through a Risk Evaluation and Mitigation Strategy (REMS) program.
6. Calcium, magnesium ...
The FDA has approved pitolisant (Wakix – Harmony), a histamine-3 (H3)-receptor antagonist/inverse agonist, for treatment of excessive daytime sleepiness (EDS) or cataplexy in adults with narcolepsy. It is the first H3-receptor antagonist/inverse agonist to become available in the US and the first non-controlled substance to receive FDA approval for these indications. Pitolisant has been available in Europe since 2016.
Antiviral Drugs for Seasonal Influenza for 2025-2026
The Medical Letter on Drugs and Therapeutics • Oct 27, 2025 (Issue 1740)
products, calcium-fortified
beverages, and products containing polyvalent cations
$169.00 11 ...
Influenza is generally a self-limited illness, but complications
including pneumonia, respiratory failure, and
death can occur, especially in persons at increased
risk (see Table 1).
Med Lett Drugs Ther. 2025 Oct 27;67(1740):169-74 doi:10.58347/tml.2025.1740a | Show Introduction Hide Introduction
Two New Drugs for Chronic ITP
The Medical Letter on Drugs and Therapeutics • Feb 09, 2009 (Issue 1305)
decreased by food, especially
foods or supplements containing polyvalent cations (e.g.
iron, calcium ...
Romiplostim (Nplate - Amgen), a recombinant fusion protein injected subcutaneously, and eltrombopag (Promacta - GlaxoSmithKline), a non-peptide taken orally, have been approved by the FDA for treatment of chronic immune thrombocytopenic purpura (ITP) refractory to corticosteroids, immunoglobulins and/or splenectomy.
Delafloxacin (Baxdela) - A New Fluoroquinolone Antibiotic
The Medical Letter on Drugs and Therapeutics • Mar 26, 2018 (Issue 1543)
as solutions containing multivalent cations such
as calcium or magnesium.
DOSAGE AND ADMINISTRATION ...
The FDA has approved delafloxacin (Baxdela –
Melinta), an anionic fluoroquinolone antibiotic, for oral
and parenteral treatment of adults with acute bacterial
skin and skin structure infections (ABSSSIs), including
those caused by methicillin-resistant Staphylococcus
aureus (MRSA). It is the first fluoroquinolone to be
approved for treatment of MRSA.
Omadacycline (Nuzyra) - A New Tetracycline Antibiotic
The Medical Letter on Drugs and Therapeutics • May 20, 2019 (Issue 1572)
, and
antacids containing aluminum, calcium or magnesium
can impair the absorption of oral tetracyclines ...
The FDA has approved omadacycline (Nuzyra – Paratek),
a semisynthetic tetracycline derivative, for once-daily
IV and oral treatment of community-acquired bacterial
pneumonia (CAP) and acute bacterial skin and skin
structure infections (ABSSSIs) in adults.
Drugs and Devices for Weight Management
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025 (Issue 1734)
has not been established
▶ Increases oxalate absorption and may increase the
risk of developing calcium oxalate kidney ...
Overweight is generally defined as a body mass
index (BMI) between 25 and 29.9 kg/m2 in adults. A
BMI ≥30 is considered obese (criteria differ slightly in
Asian patients). In patients with an elevated BMI, a
5-10% reduction in weight has been associated with
a reduction in the risk of developing type 2 diabetes,
hypertension, and dyslipidemia. Diet, exercise, and
behavior modification are the traditional methods
for losing weight, but they are often inadequate; the
American College of Cardiology no longer recommends
that all patients try lifestyle modification alone before
adding...
Med Lett Drugs Ther. 2025 Aug 4;67(1734):121-8 doi:10.58347/tml.2025.1734a | Show Introduction Hide Introduction
Acute Reactions to Drugs of Abuse
The Medical Letter on Drugs and Therapeutics • Mar 04, 2002 (Issue 1125)
central sympathetic stimulation, aspirin to decrease thrombus formation,
and nitroglycerin or a calcium ...
Acute toxic reactions to drugs of abuse continue to be important problems. Some patients may have mixed intoxications with complex combinations of signs and symptoms.
In Brief: One Drop or Two
The Medical Letter on Drugs and Therapeutics • Jun 19, 2006 (Issue 1237)
intracellular calcium levels in cardiac myocytes. It also increases protein synthesis in the myocardium, leading ...
Many prescriptions for eye drops call for instillation of 1-2 drops. But Medical Letter consultants in ophthalmology seem to agree that all eye drops should generally be given in doses of only one drop. The volume of a single drop can vary with the viscosity of the solution, the design of the dropper, and patient technique. The average volume of a drop is 35-50 microliters, but can be as high as 75 microliters. An eye brimming with fluid holds 30 microliters at best, so even one drop is often an overdose. A second either washes out the first or increases the possibility of systemic toxicity,...
Safety of Long-Term PPI Use
The Medical Letter on Drugs and Therapeutics • Aug 14, 2017 (Issue 1527)
use.7
Mechanism – Reduced gastric acidity might interfere
with calcium absorption.
Clinical Studies ...
Proton pump inhibitors (PPIs), which are used for
treatment of gastroesophageal reflux disease (GERD)
and for prevention of upper gastrointestinal adverse
effects caused by NSAIDs and aspirin, are one of
the most commonly prescribed classes of drugs in
the US. All PPIs are similarly effective and generally
well tolerated, but their long-term use has been
associated with a number of safety concerns.
Recommendations addressing these concerns have
recently been published.
